Media Releases from members of Sources.
To submit a news release, use this form.

Topic: Alzheimer Disease/Research

Click a headline to read the full article
View the News Releases Topic Index
View Sources experts on Alzheimer Disease/Research

Anavex presents data on neuroprotective evidence for ANAVEX 2-73, lead compound for Alzheimer’s disease (July 26, 2011)
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide a summary of its second poster presentation at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “Preclinical development of new tetrahydrofur
Anavex presents data on potential dual utility of ANAVEX 2-73 in both amyloid and tau pathology (July 25, 2011)
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide a summary of the first of two poster presentations at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “The novel aminotetrahydrofuran deriva
Anavex to present at Alzheimer’s Association International Conference on Alzheimer’s Disease (July 15, 2011)
Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that new data on ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease (AD) currently in Phase I clinical trials, will be presented in two poster sessions at the 2011 Alzh
Anavex raises $1.575 million (July 11, 2011)
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to announce that it has raised US$1,575,000.00 through the exercise of warrants. Funds will be used to continue the Phase I clinical trial of ANAVEX 2-73 the company’s lead drug candidate
Anavex rapidly advances ANAVEX 2-73 for Alzheimer’s disease, Phase I clinical trial progressing well (July 6, 2011)
Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) has commenced the 30 mg dose step in its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead drug candidate for Alzheimer’s disease. This is the third of six potential dose
Anavex advances second lead compound; initiates scale-up manufacturing of ANAVEX 1-41 (June 8, 2011)
Anavex Life Sciences Corp., (“Anavex”) (OTCBB: AVXL) today announced the initiation of scale-up manufacturing of ANAVEX 1-41, its lead compound for a range of important neurological diseases and a potential back-up compound to ANAVEX 2-73 in Alzheime
ANAVEX 2-73 advances Phase I clinical trial for Alzheimer’s disease (May 26, 2011)
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide an update on its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead candidate for Alzheimer’s disease. After reviewing all the safety data from the firs
Anavex comments on new Alzheimer’s disease diagnostic guidelines (May 17, 2011)
Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today commented on new diagnostic criteria and guidelines for Alzheimer’s disease published recently by the National Institute on Aging (NIA) and the Alzheimer’s Association, which have been updated
Anavex: First-In-Human Dosing Commenced in ANAVEX 2-73 Clinical Trial for Alzheimer’s Disease (April 20, 2011)
Anavex Life Sciences Corp. (OTCBB: AVXL) today announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease.
Anavex Screening Healthy Volunteers For Phase I, First-In-Human Clinical Study in Alzheimer’s Disease (March 31, 2011)
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease. ANAVEX 2-73 is the first of a new
Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease (March 21, 2011)
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority, BfArM. The
Anavex comments on President Obama’s signing of National Alzheimer’s Project Act into law (January 18, 2011)
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today commented on President Obama’s signing of the National Alzheimer’s Project Act (NAPA) into law. The passage of this landmark legislation lays the foundation for the first coordinated national
Alzheimer’s Weekly names ANAVEX 2-73 the number one most promising trial drug in Alzheimer’s disease and Anavex’s Phase I clinical program as “Trial o (January 11, 2011)
ANAVEX 2-73 has been named 2010’s “most promising trial drug” by the editorial staff at Alzheimer’s Weekly.
Anavex files Phase I regulatory submission for ANAVEX 2-73 in Alzheimer’s disease (January 11, 2011)
Anavex Life Sciences Corp. has filed regulatory submission for ANAVEX 2-73 with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, its lead compound for the treatment of Alzheimer
Anavex to present at Rodman & Renshaw Healthcare Conference September 13 in New York (September 8, 2010)
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to announce that Dr. Cameron Durrant, the company#s Executive Chairman, will be presenting at the Rodman & Renshaw 12th Annual Healthcare Conference at 4:45 pm ET on Monday, September 13
Anavex appoints contract research organizations to initiate Phase I/IIa clinical programs, regulatory strategies in Alzheimer's disease (August 10, 2010)
Anavex Life Sciences Corp signs a definitive master services agreement with Genesis BioPharma Group and ABX-CRO Advanced Pharmaceutical Services to begin clinical studies and regulatory filings for its lead compound for the treatment of Alzheimer#s.
Sources welcomes Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biotech Expert (July 23, 2010)
Sources welcomes a new member: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biotech Expert.

Publicize your views and accomplishments:

Get your news release posted and distributed by Sources

Background information and history at your fingertips:

Archive of Past News Releases: 2010
Archive of Past News Releases: 2009
Archive of Past News Releases: 2008
Older Releases

Check out newsworthy events across Canada:

The Sources Calendar
Archive of Past Events 2011
Archive of Past Events 2010
Archive of Past Events 2009
Plain HTML Version

Sources Products and Services:

Find Experts and Spokespersons in the Sources Directory
Include yourself in the Sources Directory
Media Names & Numbers
Parliamentary Names & Numbers

Sources is a service for journalists, writers, news editors, researchers. Use Sources to find experts, media contacts, spokespersons, scientists, lobbyists, officials, speakers, university professors, researchers, newsmakers, CEOs, executive directors, media relations contacts, spokespeople, talk show guests, PR representatives, Canadian sources, story ideas, research studies, databases, universities, colleges, associations, businesses, government, research institutions, lobby groups, non-government organizations (NGOs), in Canada and internationally.

Sources Content Checklist:
Who: Sources - Experts - Media Contacts - Spokespersons - Scientists - Lobbyists - Officials - News Sources - Speakers - Representatives - University Professors - Researchers - Authorities - Newsmakers - CEOs - Executive Directors - Media Relations Contacts - Spokespeople - Guests - Talking Heads - PR representatives - Media Sources.
Where: Universities - Associations - Business - Government - Research Institutions - Lobby Groups - Non-Government Organizations (NGOs) - Colleges - Campuses - Canada - Canadian - International.
What: Searchable Directory of Experts & Topics - Browseable Listings & Subject Index - Intelligent Search Technology - Event Calendar - News Releases - Story Ideas - Statements - Studies - Research - News - Journalism Resources - Articles - Announcements - Press Conferences - Links - Search Tools - Government & Media Directories.
Find: Experts - Ideas - Content - Events - Sources - News - Stories - Press Releases - Databases - Reference Materials - Studies - Guides - Indexes - Journalism Awards.
For: Journalists - Reporters - Researchers - Writers - Editors - Authors - Producers - Fact Checkers - Interviewers - Hosts - Talk Shows - Interviews - Public Relations Professionals - Academics - Anyone who who needs knowledgeable sources.
Francais: Actualite - Actualites - Agences de contenu - Agents intelligents - Annuaire de médias - Autour d'Internet - Base de données de médias - Bibliotheques - Canadien - Clavardage - Communiqués de presse - Courrier - Cyberjournalisme - Cyberjournaliste - Dictionnaires - Donnees - échafaudage d'événement - Ecriture multimedia - Encyclopedies - Evaluation des sources - Gestion du site - Groupes de communication - Groupes de presse - Informations commerciales - Journalisme - Journaliste - Journalistes - Journaux - Librairies - Listes - Marchés des actions - Médias surveillant - Moteurs specialises - Multimédia - Nouvelles - Nouvelles libère - Nouvelles surveillant - Outils de médias - Presse alternative - Promotion du site - Recherche - References - Relations d'investisseur - Relations publiques - Reportage financier - Ressources - Révélation - Services d'émission - Sources d'information - Sources institutionnelles - Traduction.
Deutsch: Abonnements - Adresssuche - Agenturen - Agenturmeldungen - Archiv - Archive - Diskussionsforen - Experten - Expertenmakler - Fachmagazine - Fachzeitschriften - Infos - Internationale Presse - Journalismus - Journalisten - Journalistenschulen - Kanada - Kataloge - Kommentierte Links - Lexika - Lexikon - Medien - Medienprofis - Meldungen - Nachrichten - Nachrichtenagenturen - Nachschlagewerke - Onlineversionen - Portal - Presse - Pressearchive - Pressekonditionen - Pressesprecher - Quelle - Recherche - Recherchen - Recherchieren im Internet - Regionale Presse - Regionale Wochenzeitungen - Regionalzeitungen - Schlagzeilen - Statistiken - Suchmaschinen - Suchtipps - Tageszeitungen - Telefonauskunft - Telefonbuch - Telefonbucher - Telefontarife - Themenplanung - Weltatlas - Wochenzeitungen - Zeitschriften - Zeitung - Zeitungen - Zeitungsarchiv.


Find Experts & Sources Media Resources Releases Subject Index Releases List Event Calendar Submit a news release or Calendar event Include yourself in SOURCES FAQ Membership Form Be an Affiliate Sources Shop Powerful Tools Tell your story Internet Power Media Directory Media Releases Sources Bookshelf Sources Newsstand Media training Testimonials Government Directory Subscriptions Services Overview Awards & Prizes Sources HotLink Sources Select Resources Twitter Download PDFs Contact	Media Releases from members of Sources. To submit a news release, use this form. Topic: Alzheimer Disease/Research Click a headline to read the full article View the News Releases Topic Index View Sources experts on Alzheimer Disease/Research Anavex presents data on neuroprotective evidence for ANAVEX 2-73, lead compound for Alzheimer’s disease (July 26, 2011) Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide a summary of its second poster presentation at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “Preclinical development of new tetrahydrofur Anavex presents data on potential dual utility of ANAVEX 2-73 in both amyloid and tau pathology (July 25, 2011) Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide a summary of the first of two poster presentations at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “The novel aminotetrahydrofuran deriva Anavex to present at Alzheimer’s Association International Conference on Alzheimer’s Disease (July 15, 2011) Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that new data on ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease (AD) currently in Phase I clinical trials, will be presented in two poster sessions at the 2011 Alzh Anavex raises $1.575 million (July 11, 2011) Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to announce that it has raised US$1,575,000.00 through the exercise of warrants. Funds will be used to continue the Phase I clinical trial of ANAVEX 2-73 the company’s lead drug candidate Anavex rapidly advances ANAVEX 2-73 for Alzheimer’s disease, Phase I clinical trial progressing well (July 6, 2011) Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) has commenced the 30 mg dose step in its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead drug candidate for Alzheimer’s disease. This is the third of six potential dose Anavex advances second lead compound; initiates scale-up manufacturing of ANAVEX 1-41 (June 8, 2011) Anavex Life Sciences Corp., (“Anavex”) (OTCBB: AVXL) today announced the initiation of scale-up manufacturing of ANAVEX 1-41, its lead compound for a range of important neurological diseases and a potential back-up compound to ANAVEX 2-73 in Alzheime ANAVEX 2-73 advances Phase I clinical trial for Alzheimer’s disease (May 26, 2011) Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide an update on its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead candidate for Alzheimer’s disease. After reviewing all the safety data from the firs Anavex comments on new Alzheimer’s disease diagnostic guidelines (May 17, 2011) Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today commented on new diagnostic criteria and guidelines for Alzheimer’s disease published recently by the National Institute on Aging (NIA) and the Alzheimer’s Association, which have been updated Anavex: First-In-Human Dosing Commenced in ANAVEX 2-73 Clinical Trial for Alzheimer’s Disease (April 20, 2011) Anavex Life Sciences Corp. (OTCBB: AVXL) today announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease. Anavex Screening Healthy Volunteers For Phase I, First-In-Human Clinical Study in Alzheimer’s Disease (March 31, 2011) Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease. ANAVEX 2-73 is the first of a new Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease (March 21, 2011) Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority, BfArM. The Anavex comments on President Obama’s signing of National Alzheimer’s Project Act into law (January 18, 2011) Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today commented on President Obama’s signing of the National Alzheimer’s Project Act (NAPA) into law. The passage of this landmark legislation lays the foundation for the first coordinated national Alzheimer’s Weekly names ANAVEX 2-73 the number one most promising trial drug in Alzheimer’s disease and Anavex’s Phase I clinical program as “Trial o (January 11, 2011) ANAVEX 2-73 has been named 2010’s “most promising trial drug” by the editorial staff at Alzheimer’s Weekly. Anavex files Phase I regulatory submission for ANAVEX 2-73 in Alzheimer’s disease (January 11, 2011) Anavex Life Sciences Corp. has filed regulatory submission for ANAVEX 2-73 with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, its lead compound for the treatment of Alzheimer Anavex to present at Rodman & Renshaw Healthcare Conference September 13 in New York (September 8, 2010) Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to announce that Dr. Cameron Durrant, the company#s Executive Chairman, will be presenting at the Rodman & Renshaw 12th Annual Healthcare Conference at 4:45 pm ET on Monday, September 13 Anavex appoints contract research organizations to initiate Phase I/IIa clinical programs, regulatory strategies in Alzheimer's disease (August 10, 2010) Anavex Life Sciences Corp signs a definitive master services agreement with Genesis BioPharma Group and ABX-CRO Advanced Pharmaceutical Services to begin clinical studies and regulatory filings for its lead compound for the treatment of Alzheimer#s. Sources welcomes Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biotech Expert (July 23, 2010) Sources welcomes a new member: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biotech Expert. Publicize your views and accomplishments: Get your news release posted and distributed by Sources Background information and history at your fingertips: Archive of Past News Releases: 2010 Archive of Past News Releases: 2009 Archive of Past News Releases: 2008 Older Releases Check out newsworthy events across Canada: The Sources Calendar Archive of Past Events 2011 Archive of Past Events 2010 Archive of Past Events 2009 Plain HTML Version Sources Products and Services: Find Experts and Spokespersons in the Sources Directory Include yourself in the Sources Directory Media Names & Numbers Parliamentary Names & Numbers Sources is a service for journalists, writers, news editors, researchers. Use Sources to find experts, media contacts, spokespersons, scientists, lobbyists, officials, speakers, university professors, researchers, newsmakers, CEOs, executive directors, media relations contacts, spokespeople, talk show guests, PR representatives, Canadian sources, story ideas, research studies, databases, universities, colleges, associations, businesses, government, research institutions, lobby groups, non-government organizations (NGOs), in Canada and internationally. Sources Content Checklist: Who: Sources - Experts - Media Contacts - Spokespersons - Scientists - Lobbyists - Officials - News Sources - Speakers - Representatives - University Professors - Researchers - Authorities - Newsmakers - CEOs - Executive Directors - Media Relations Contacts - Spokespeople - Guests - Talking Heads - PR representatives - Media Sources. Where: Universities - Associations - Business - Government - Research Institutions - Lobby Groups - Non-Government Organizations (NGOs) - Colleges - Campuses - Canada - Canadian - International. What: Searchable Directory of Experts & Topics - Browseable Listings & Subject Index - Intelligent Search Technology - Event Calendar - News Releases - Story Ideas - Statements - Studies - Research - News - Journalism Resources - Articles - Announcements - Press Conferences - Links - Search Tools - Government & Media Directories. Find: Experts - Ideas - Content - Events - Sources - News - Stories - Press Releases - Databases - Reference Materials - Studies - Guides - Indexes - Journalism Awards. For: Journalists - Reporters - Researchers - Writers - Editors - Authors - Producers - Fact Checkers - Interviewers - Hosts - Talk Shows - Interviews - Public Relations Professionals - Academics - Anyone who who needs knowledgeable sources. Francais: Actualite - Actualites - Agences de contenu - Agents intelligents - Annuaire de médias - Autour d'Internet - Base de données de médias - Bibliotheques - Canadien - Clavardage - Communiqués de presse - Courrier - Cyberjournalisme - Cyberjournaliste - Dictionnaires - Donnees - échafaudage d'événement - Ecriture multimedia - Encyclopedies - Evaluation des sources - Gestion du site - Groupes de communication - Groupes de presse - Informations commerciales - Journalisme - Journaliste - Journalistes - Journaux - Librairies - Listes - Marchés des actions - Médias surveillant - Moteurs specialises - Multimédia - Nouvelles - Nouvelles libère - Nouvelles surveillant - Outils de médias - Presse alternative - Promotion du site - Recherche - References - Relations d'investisseur - Relations publiques - Reportage financier - Ressources - Révélation - Services d'émission - Sources d'information - Sources institutionnelles - Traduction. Deutsch: Abonnements - Adresssuche - Agenturen - Agenturmeldungen - Archiv - Archive - Diskussionsforen - Experten - Expertenmakler - Fachmagazine - Fachzeitschriften - Infos - Internationale Presse - Journalismus - Journalisten - Journalistenschulen - Kanada - Kataloge - Kommentierte Links - Lexika - Lexikon - Medien - Medienprofis - Meldungen - Nachrichten - Nachrichtenagenturen - Nachschlagewerke - Onlineversionen - Portal - Presse - Pressearchive - Pressekonditionen - Pressesprecher - Quelle - Recherche - Recherchen - Recherchieren im Internet - Regionale Presse - Regionale Wochenzeitungen - Regionalzeitungen - Schlagzeilen - Statistiken - Suchmaschinen - Suchtipps - Tageszeitungen - Telefonauskunft - Telefonbuch - Telefonbucher - Telefontarife - Themenplanung - Weltatlas - Wochenzeitungen - Zeitschriften - Zeitung - Zeitungen - Zeitungsarchiv.

Media Resources

Topic: Alzheimer Disease/Research